Keep track of dates in terms of fractional calendar months 
  per Damien Laker "Time Calculations for Annualizing Returns: the Need for Standardization", 
  The Journal of Performance Measurement, 2008.
  Model dates as of close of business.
  Perform date arithmetic in units of "months" and "years".
  Allow "infinite" dates to model "ultimate" time.

The unique function of this package allows representing in a single graph the relative occurrence and co-occurrence of events measured in a sample. 
  As examples, the package was applied to describe the occurrence and co-occurrence of different species of bacterial or viral symbionts infecting arthropods at the individual level. The graphics allows determining the prevalence of each symbiont and the patterns of multiple infections (i.e. how different symbionts share or not the same individual hosts). 
  We named the package after the famous painter as the graphical output recalls Mondrian’s paintings.

High-performance MongoDB client based on 'mongo-c-driver' and 'jsonlite'.
    Includes support for aggregation, indexing, map-reduce, streaming, encryption,
    enterprise authentication, and GridFS. The online user manual provides an overview 
    of the available methods in the package: <https://jeroen.github.io/mongolite/>.

Translate R code into MongoDB aggregation pipelines.

Acoustic template detection and monitoring database interface. Create, modify, save, and use templates for detection of animal vocalizations. View, verify, and extract results. Upload a MySQL schema to a existing instance, manage survey metadata, write and read templates and detections locally or to the database.

These guidelines are meant to provide a pragmatic, yet rigorous, help to drug developers and decision makers, since they are shaped by three fundamental ingredients: the clinically determined margin of detriment on OS that is unacceptably high (delta null); the benefit on OS that is plausible given the mechanism of action of the novel intervention (delta alt); and the quantity of information (i.e. survival events) it is feasible to accrue given the clinical and drug development setting. The proposed guidelines facilitate transparent discussions between stakeholders focusing on the risks of erroneous decisions and what might be an acceptable trade-off between power and the false positive error rate.